Kevin Balthaser - Sep 1, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Financial Officer
Signature: /s/ Matthew Rothman, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Sep 1, 2024
Transactions value $: -$337
Form type: 4
Date filed: 9/4/2024, 07:52 PM
Previous filing: Mar 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+1K	+4.17%		25K	Sep 1, 2024	Direct	F1
transaction	ACRS	Common Stock	Tax liability	-$337	-286	-1.14%	$1.18	24.7K	Sep 1, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-1K	-100%	$0.00	0	Sep 1, 2024	Common Stock	1K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2	The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vested on September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.